This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Elevra Breaks Ground on Fully Funded North American Lithium Expansion

Tipranks - Tipranks - Mon Jun 29, 5:56PM CDT

End of Quarter Sale - 70% Off

Elevra Lithium ( (AU:ELV) ) has provided an update.

Elevra Lithium has broken ground on its fully funded North American Lithium Expansion Project, following a May 2026 capital raise that strengthened its balance sheet and secured financing for staged growth. The company has already ordered key equipment to support the development schedule and mitigate execution risks at the operation in Québec.

Stage 1 of the expansion, targeted for completion by mid-2027, is expected to lift annual spodumene concentrate capacity by 15–20% while lowering unit operating costs through scale and efficiency gains. The project is intended to reinforce Elevra’s role as a strategically important domestic supplier of traceable lithium to North America’s rapidly growing electric vehicle and energy storage sectors, aligning with regional efforts to reduce reliance on external battery material sources.

The most recent analyst rating on (AU:ELV) stock is a Buy
with a A$14.50 price target.
To see the full list of analyst forecasts on Elevra Lithium stock,
see the AU:ELV Stock Forecast page.

More about Elevra Lithium

Elevra Lithium Limited is a North American-focused lithium producer listed on the ASX and NASDAQ, with projects in Québec, the United States and Western Australia. Its portfolio includes full ownership of the North American Lithium operation and the Carolina Lithium project, a majority stake in the Moblan Lithium Project, and extensive tenements in Western Australia’s Pilbara region prospective for gold and lithium.

YTD Price Performance: 19.03%

Average Trading Volume: 2,219,698

Technical Sentiment Signal: Hold

Current Market Cap: A$1.84B

For a thorough assessment of ELV stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).